Obviously I am sympathetic to this paper as I think mtDNA damage is the development and aging clock. (senescence has an additional effect)
https://www.nature.com/articles/s41391-026-01097-5
chatGPT:
Summary
This is a 2026 review article on the idea that mitochondrial dysfunction may be a shared biological mechanism behind several non-malignant urologic disorders, especially lower urinary tract symptoms (LUTS). The paper covers LUTS linked with aging, inherited mitochondrial disease, metabolic syndrome, diabetes, benign prostatic hyperplasia (BPH), bladder dysfunction, and stress urinary incontinence (SUI). Its central claim is not that mitochondria have been proven to cause these conditions, but that enough evidence now exists to treat mitochondrial dysfunction as a serious candidate mechanism and possible therapeutic target.
The review begins by outlining mitochondrial biology: mtDNA, heteroplasmy, oxidative phosphorylation, the electron transport chain, ROS production, mitochondrial biogenesis, and nuclear regulators such as PGC-1α, NRF-1/2 and TFAM. The paper stresses that mtDNA is especially vulnerable to damage because it is close to oxidative phosphorylation and lacks histone protection; mtDNA mutations and heteroplasmy can impair electron transport chain function and increase oxidative stress.
The review then links mitochondrial dysfunction to LUTS in several ways:
Inherited mitochondrial disease: Patients with confirmed mitochondrial disorders appear to have higher rates of urinary symptoms, including incontinence and retention. One cited adult study found LUTS in 83.7% of patients with mitochondrial disease versus 68.8% of controls, and a paediatric study found urinary retention in 73% of symptomatic children.
Metabolic syndrome: Hypertension, obesity, visceral fat, hyperglycaemia and cholesterol are all associated with LUTS. The paper argues that mitochondrial dysfunction may connect metabolic syndrome, inflammation, oxidative stress and LUTS, although it admits the causal chain is not established.
Diabetes: The article reviews mitochondrial defects in pancreatic islets and skeletal muscle in diabetes, then links diabetes to diabetic bladder dysfunction, overactive bladder, poor contractility, urinary retention and increased LUTS. It cites NHANES data showing LUTS in 52.7% of people with diabetes versus 36.5% in the wider study population. However, evidence specific to diabetic bladder mitochondrial dysfunction remains mainly correlative or animal-based.
BPH/prostate dysfunction: This is one of the stronger sections. The authors discuss reduced expression of the mitochondrial complex I protein NDUFS3 in BPH tissue and aged mouse models, and suggest complex I dysfunction may contribute to a pro-fibrotic prostate phenotype. They also highlight a provocative finding that finasteride and NSAIDs/celecoxib may reduce NDUFS3 expression, potentially worsening mitochondrial dysfunction or contributing to treatment failure.
Bladder dysfunction: Human and animal studies are cited showing reduced mitochondrial enzymes, structural mitochondrial damage, altered mtDNA content, increased ROS, reduced respiration and impaired recovery after outlet obstruction. The authors suggest mitochondrial status may influence whether bladder function recovers after obstruction is relieved.
Stress urinary incontinence: The review links SUI and pelvic organ prolapse to mitochondrial swelling, oxidative stress, increased 8-OHdG and 4-HNE, reduced mtDNA content, altered mitophagy and mitochondrial mutations. It suggests mitochondrial dysfunction may contribute to pelvic floor/rhabdosphincter weakening rather than simply being a passive consequence of age.
The table on page 5 is useful because it separates direct urogenital mitochondrial phenotypes from more indirect systemic links. Direct evidence is strongest for BPH, bladder dysfunction and SUI; indirect evidence is used for inherited mitochondrial disease, metabolic syndrome and diabetes.
What is novel or interesting
The main novelty is conceptual integration. The paper does not present new experimental data; its novelty is that it frames mitochondrial dysfunction as a possible common intersection across multiple LUTS-associated disorders that are usually studied separately: BPH, diabetes, metabolic syndrome, bladder obstruction, SUI and aging.
A second notable point is the emphasis on non-malignant urologic disease. Mitochondria are heavily studied in cancer, neurology, cardiology, diabetes and aging, but the paper argues that urology has under-investigated mitochondria outside cancer. That positioning is useful because LUTS are highly prevalent but mechanistically heterogeneous.
The most striking specific claim is the BPH treatment angle: the review discusses evidence that finasteride and celecoxib may reduce NDUFS3, a mitochondrial complex I protein, in BPH tissue. If correct, this raises the possibility that some current treatments might partly interact with mitochondrial dysfunction rather than simply relieving symptoms. That is probably one of the most clinically provocative ideas in the review.
Another useful novelty is the distinction between mitochondrial dysfunction as cause, amplifier, consequence, or recovery-limiting factor. In bladder outlet obstruction, for example, mitochondria may not initiate the obstruction, but mitochondrial damage may affect whether the bladder recovers after obstruction is relieved.
The paper also suggests that mitochondrial modulators such as MitoQ, quercetin-like agents, antioxidants or other mitochondrial-targeted therapies should be considered for LUTS, especially because mitochondrial dysfunction may cut across several age-related urologic phenotypes.
Critique
The review is useful, but its central thesis remains hypothesis-generating rather than proven. The authors themselves acknowledge that much of the evidence is correlative and that it remains unclear whether mitochondrial dysfunction is an inducer of disease or a by-product of other cellular pathology.
The paper uses a very broad definition of “mitochondrial dysfunction”. This includes oxidative stress, altered mtDNA copy number, reduced mitochondrial proteins, structural damage, reduced respiration, altered mitophagy and mitochondrial mutations. That breadth is scientifically reasonable for a review, but it also weakens causal precision. Many chronic diseases show oxidative stress and mitochondrial changes, so the review sometimes risks treating mitochondrial dysfunction as a general marker of tissue stress rather than a specific mechanism.
The evidence base is uneven. BPH and bladder dysfunction have more direct tissue-level evidence, including prostate proteins, bladder biopsies, outlet obstruction models and mitochondrial morphology. By contrast, metabolic syndrome and diabetes are linked more indirectly: the paper shows that metabolic disease involves mitochondrial dysfunction and that metabolic disease is associated with LUTS, but this does not by itself show that mitochondrial dysfunction causes the urinary phenotype.
There is also a risk of confounding by aging. Aging is linked to LUTS, BPH, diabetes, metabolic syndrome, pelvic floor dysfunction and mitochondrial decline. Without longitudinal or interventional evidence, it is difficult to know whether mitochondria are an independent driver or simply one of many aging-associated changes.
The treatment implications are premature. The suggestion that mitochondrial modulators might help LUTS is plausible, but the paper does not yet show that mitochondrial-targeted interventions improve clinically meaningful urinary outcomes in humans. Antioxidant or mitochondrial-support strategies often look promising mechanistically but fail to translate cleanly because ROS are also signalling molecules, and mitochondrial dysfunction can be highly tissue- and context-specific.
The review also lacks a clear mechanistic hierarchy. For example, in BPH, is the key process complex I dysfunction, ROS, fibrosis, altered stromal metabolism, inflammation, androgen signalling, or impaired mitophagy? In SUI, is mitochondrial dysfunction primary in muscle cells, connective tissue, nerves, vascular supply, or a response to mechanical stress? The paper identifies associations but does not yet resolve which mitochondrial defect matters most in each disease.
Finally, the search strategy is not a full systematic review. It used PubMed and disease-specific searches, excluded urologic conditions with fewer than three relevant mitochondrial publications, and focused on human/clinical studies where possible. That is reasonable for a narrative review, but it means publication bias and selection bias remain possible.
Bottom line
This is a strong field-mapping review rather than a definitive causal paper. Its best contribution is to argue that mitochondrial dysfunction deserves more attention in non-cancer urology, especially in BPH, bladder dysfunction and SUI. The most convincing parts are where mitochondrial abnormalities are shown directly in urogenital tissues. The weaker parts are where the argument depends on broad systemic links between aging, metabolic disease, oxidative stress and LUTS.
The key next step would be interventional evidence: show that correcting a defined mitochondrial defect in prostate, bladder, pelvic floor or urothelium improves a specific urinary phenotype in humans or robust animal models.